EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chimeric enzymes enhance treatment potential for globoid cell leukodystrophy through hematopoietic stem cell gene therapy

Federica Cascino, Alessandra Ricca, Ilaria Picciotti, Erika Valeri, Giulia Unali, Veronica Saporito, Marta Freschi, Francesco Morena, Sabata Martino, Anna Kajaste-Rudnitski, Angela Gritti

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.09.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Federica Cascino und 10 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy. Hauptthemen laut MEDLINE: Genetic Therapy, Leukodystrophy, Globoid Cell, Galactosylceramidase, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Leukodystrophies Association, Ministry of Health, Fondazione Centro San Raffaele.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Globoid cell leukodystrophy (GLD) is a fatal lysosomal storage disorder caused by a deficiency in the β-galactosylceramidase (GALC) enzyme, leading to severe demyelination and neurodegeneration, and often death before the age of 2 years. Hematopoietic stem/progenitor cell transplantation (HSPC-T) has limited efficacy due to inadequate GALC delivery to the central (CNS) and peripheral nervous systems (PNS) and associated risks. In vivo gene therapy (GT) using adeno-associated viral vectors shows promise, but safety concerns persist. This research presents a strategy using lentiviral (LV) vector-mediated ex vivo HSPC-GT with a chimeric GALC enzyme that incorporates peptides from α-l-iduronidase (IDUA) and apolipoprotein E II (APO) to enhance expression and blood-brain barrier penetration. The chimeric IDUAsp.GALC.APO enzyme exhibited superior production and secretion compared to native GALC and previous chimeric variants in LV-transduced HSPCs, resulting in improved cross-correction and normalization of GALC activity in GLD neural cells. Proof-of-concept studies demonstrated effective enzyme production, secretion, and cross-correction capability of macrophages from GLD patients. In vivo results showed stable gene marking, sustained enzyme production, and efficient delivery of the chimeric GALC in affected organs, including the CNS and PNS. These findings highlight the potential of HSPC-GT using chimeric GALC enzymes as an innovative therapeutic approach for treating GLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyLeukodystrophy, Globoid CellGalactosylceramidaseHematopoietic Stem Cell TransplantationHematopoietic Stem CellsIduronidaseRecombinant Fusion ProteinsHumansAnimalsGenetic VectorsMiceLentivirusDisease Models, AnimalBlood-Brain BarrierTransduction, GeneticGene Expression

Stichwörter der Autor:innen

Krabbe diseasechimeric enzymescross-correctiongene therapygloboid cell leukodystrophyhematopoietic stem/progenitor cellslentiviral vectorsmetabolic diseasesstem cell transplant

Substanzen

GalactosylceramidaseIduronidaseRecombinant Fusion Proteins

Autor:innen und Institutionen

  • IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy.
  • IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy; Research Institute of Molecular Pathology (IMP), 1030 Vienna, Austria.
  • IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy; National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118,…
  • IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy; Gene Therapy Program of Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, M…
  • Department of Chemistry, Biology, and Biotechnology, University of Perugia, 06122 Perugia, Italy.
  • IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 20132 Milan, Italy; Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy.

Förderung

  • European Leukodystrophies Association
  • Ministry of Health
  • Fondazione Centro San Raffaele
  • Fondazione Telethon

Zitieren

APA

Cascino, F., Ricca, A., Picciotti, I., Valeri, E., Unali, G., Saporito, V., Freschi, M., Morena, F., Martino, S., Kajaste-Rudnitski, A., & Gritti, A. (2025). Chimeric enzymes enhance treatment potential for globoid cell leukodystrophy through hematopoietic stem cell gene therapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.09.030

Vancouver

Cascino F, Ricca A, Picciotti I, Valeri E, Unali G, Saporito V, et al. Chimeric enzymes enhance treatment potential for globoid cell leukodystrophy through hematopoietic stem cell gene therapy. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.09.030

BibTeX
@article{Cascino2025,
  author = {Cascino, Federica and Ricca, Alessandra and Picciotti, Ilaria and Valeri, Erika and Unali, Giulia and Saporito, Veronica and Freschi, Marta and Morena, Francesco and Martino, Sabata and Kajaste-Rudnitski, Anna and Gritti, Angela},
  title = {Chimeric enzymes enhance treatment potential for globoid cell leukodystrophy through hematopoietic stem cell gene therapy},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.09.030}
}
Kostenlos starten →